Adjuvant Cemiplimab Improves Disease-Free Survival in High-Risk Cutaneous SCC

Adjuvant Cemiplimab Improves Disease-Free Survival in High-Risk Cutaneous SCC

(MedPage Today) -- CHICAGO -- Adjuvant cemiplimab (Libtayo) significantly improved disease-free survival (DFS) compared with placebo in patients at high risk of recurrence of cutaneous squamous-cell carcinoma (SCC), a phase III randomized trial...

Immunotherapy Strategies in Cutaneous Squamous Cell Carcinoma: ASCO25 Insights

Shlomo Koyfman, MD, discusses the MK-3475-630/​KEYNOTE-630 trial, which focused on patients with high-risk cutaneous squamous cell cancer.

ASCO25: Regeneron unpacks positive Libtayo data in adjuvant CSCC as Keytruda stumbles

Additional data presented at ASCO highlights Libtayo’s ability to hold off recurrence of a type of skin cancer.The post ASCO25: Regeneron unpacks positive Libtayo data in adjuvant CSCC as Keytruda stumbles appeared first on Clinical Trials Arena.

ASCO25: Regeneron unpacks positive Libtayo data in adjuvant CSCC as Keytruda stumbles - Pharmaceutical Technology

Additional data presented at ASCO highlights Libtayo’s ability to hold off recurrence of a type of skin cancer.